Silexion Therapeutics Corp (SLXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,519 | -5,108 | 584 | -755 | -196 |
| Depreciation Amortization | 25 | 45 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | 610 | 79 | N/A | N/A | N/A |
| Other Working Capital | -1,580 | 87 | 363 | -470 | 121 |
| Other Operating Activity | 9,068 | 368 | -131 | -182 | 0 |
| Operating Cash Flow | $-8,396 | $-4,529 | $816 | $-1,407 | $-75 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -22 | 66 | N/A | N/A | N/A |
| Other Investing Activity | 0 | 507 | 0 | 0 | 0 |
| Investing Cash Flow | $-22 | $573 | $0 | $0 | $0 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 890 | 320 | 150 |
| Common Stock Issued | 3,054 | N/A | N/A | 118,800 | 25 |
| Other Financing Activity | 2,050 | 522 | 0 | -2,719 | -48 |
| Financing Cash Flow | $5,104 | $522 | $890 | $116,401 | $127 |
| Exchange Rate Effect | -61 | -230 | N/A | N/A | N/A |
| Beginning Cash Position | 4,645 | 8,309 | 115,045 | 52 | 0 |
| End Cash Position | 1,270 | 4,645 | 116,752 | 115,045 | 52 |
| Net Cash Flow | $-3,375 | $-3,664 | $1,706 | $114,994 | $52 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,396 | -4,529 | 816 | -1,407 | -75 |
| Capital Expenditure | -22 | -12 | N/A | N/A | N/A |
| Free Cash Flow | -8,418 | -4,541 | 816 | -1,407 | -75 |